[AGN] Allergan plc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 96.6 B

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 198.87 Change: 4.89 (2.52%)
Ext. hours: Change: 0 (0%)

chart AGN

Refresh chart

Strongest Trends Summary For AGN

AGN is in the long-term up 583% in 18 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding395.56 M EPS EPS Growth - 4 Quarters115.47% EPS Growth - Q/Q75.5%
EPS Growth - Y/Y58.22% Sales Growth - 4 Quarters 16.06% Sales Growth - Q/Q5.14% P/E
P/E To EPS Growth0.57 P/S13.35 P/BV12.46 Price/Cash Per Share19.45
Price/Free Cash Flow57.37 ROA12.28% ROE19.66% ROI14.05%
Current Ratio4.41 Quick Ratio4.22 Long Term Debt/Equity0.39 Debt Ratio0.2
Gross Margin88.36% Operating Margin27.76% Net Profit Margin21.06% Dividend Payout Ratio-3.91%
Dividend Yield-0.06%
Fundamental Data
Cash From Financing Activities Cash From Investing Activities183.4 M Cash From Operating Activities144.6 M Gross Profit1.7 B
Net Profit694.2 M Operating Profit626.7 M Total Assets12.42 B Total Current Assets6.87 B
Total Current Liabilities1.56 B Total Debt2.09 B Total Liabilities4.66 B Total Revenue1.91 B
Technical Data
High 52 week254.35 Low 52 week163.58 Last close181.33 Last change0.94%
RSI76.15 Average true range4 Beta0.66 Volume3.21 M
Simple moving average 20 days5.72% Simple moving average 50 days5.79% Simple moving average 200 days-14.33%
Performance Data
Performance Week2.38% Performance Month6.1% Performance Quart-2.72% Performance Half-26.68%
Performance Year-14.39% Performance Year-to-date10.85% Volatility daily1.51% Volatility weekly3.37%
Volatility monthly6.91% Volatility yearly23.95% Relative Volume226.12% Average Volume3.42 M
New High New Low


2019-03-18 13:36:00 | Big Pharma Earnings Might Not Be as Good as They Look

2019-03-18 09:01:01 | The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

2019-03-18 07:30:00 | Allergan Announces FDA Approval of AVYCAZ® ceftazidime and avibactam for Pediatric Patients

2019-03-18 00:43:08 | Group with consumer-friendly vibe pushes drugmakers'

2019-03-15 10:31:02 | Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others

2019-03-14 07:30:00 | Allergan to Present New Data - _Extended Duration of Intraocular Pressure IOP Control with Intracameral Bimatoprost Sustained-Release SR Implant_ -- Highlighting Clinical Advances at the American Glaucoma Society Annual Meeting

2019-03-12 10:28:47 | See what the IHS Markit Score report has to say about Allergan plc.

2019-03-12 10:20:02 | Allergan Announces FDA Acceptance of Migraine Candidate NDA

2019-03-11 15:41:00 | Allergan Stock Could Get a Boost From a Company Breakup, Analyst Says

2019-03-11 09:40:01 | Is Allergan AGN a Worthy Pick ForValue Investors Now?

2019-03-11 07:30:00 | Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine

2019-03-10 09:19:55 | Did Changing Sentiment Drive Allergan’s NYSE:AGN Share Price Down A Worrying 51%?

2019-03-09 10:03:02 | [$$] Why Allergan Shareholders Love Bad News

2019-03-08 14:22:00 | Allergan Stock’s Comeback Has Stalled, but CEO Brent Saunders Is Buying

2019-03-07 16:53:19 | Why News From J&J, Allergan Could Be A Boon For This Biotech Stock

2019-03-07 16:20:00 | Could Kroger Lose the Grocery Wars Over This Challenge?

2019-03-07 13:20:00 | Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

2019-03-07 12:17:00 | Allergan Stock Is Up, but Investors Are Worried About Its Drug Pipeline

2019-03-07 11:37:07 | US STOCKS-Dovish ECB stance pushes Wall St to fourth day of losses

2019-03-07 11:28:36 | Appaloosa steps up pressure on Allergan after failed drug trials

2019-03-07 10:54:13 | Allergan's Depression Drug Letdown Largely Expected: Analysts Focus On Remainder Of Pipeline

2019-03-07 10:20:00 | Allergan Rises After FDA Accepts License Applications for Botox Supplements

2019-03-07 08:48:01 | Allergan's Depression Candidate Fails in Studies, Stock Down

2019-03-07 08:00:00 | FDA Accepts Supplemental Biologics License Applications sBLAs for BOTOX® onabotulinumtoxinA for Pediatric Patients with Upper and Lower Limb Spasticity

2019-03-07 03:29:00 | Stocks - Kroger Plunges in Premarket, American Eagle Outfitters, Allergan Drop

2019-03-06 19:42:00 | Today's After-Hours News: Allergan and American Eagle Are Trading Lower

2019-03-06 17:02:09 | Stocks making the biggest moves after hours: American Eagle, Allergan and more

2019-03-06 16:28:00 | Allergan stock falls after depression study fails

2019-03-06 16:17:00 | Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder MDD

2019-03-06 12:54:00 | Stocks Moving After Hours: Barnes & Noble, Rosetta Stone, American Eagle, GE

2019-03-06 08:50:01 | J&J's JNJ Nasal Spray Spravato Gets FDA Nod for Depression

2019-03-04 10:12:03 | Okta OKTA to Report Q4 Earnings: How Are Things Shaping Up?

2019-03-04 07:30:00 | Allergan to Present at The Cowen and Company 39th Annual Health Care Conference

2019-03-01 07:30:00 | Allergan Presents Data From Seven Abstracts At The 2019 American Academy of Dermatology AAD in Washington D.C.

2019-02-28 23:22:07 | Editas Medicine Inc EDIT Q4 2018 Earnings Conference Call Transcript

2019-02-28 15:02:21 | Allergan shareholder Chevedden backs Appaloosa's proposal to split CEO-chairman role

2019-02-27 07:19:12 | Editas EDIT to Report Q4 Earnings: What's in the Cards?

2019-02-22 09:40:22 | Where’s the ‘Next Warren Buffett’ Placing His Bets?

2019-02-22 08:08:39 | Why Twenty-First Century Fox Remains Seth Klarman’s Favorite Bet

2019-02-21 09:47:00 | 2 Frustrating Flops, Plus Welcome to the Wrinkle Wars

2019-02-21 07:20:00 | Research Report Identifies SS&C Technologies, Allergan plc, CorMedix, The Allstate, Vedanta, and Lexicon Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-02-20 09:08:02 | Allergan Responds to Investor's Call for CEO/Chair Role Split

2019-02-19 16:05:01 | Allergan should explore selling itself: Appaloosa's Tepper

2019-02-19 16:05:01 | Allergan should explore selling itself: Appaloosa's Tepper

2019-02-19 15:32:00 | FINAL DEADLINE ALERT: Lead Plaintiff Deadline - February 19, 2019 - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc AGN

2019-02-19 14:55:31 | CLASS ACTION UPDATE for ARLO, AGN, DXC and MAXR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-19 13:00:00 | Allergan Responds to Public Shareholder Letter

2019-02-19 12:32:00 | FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc AGN & Lead Plaintiff Deadline -- February 19, 2019

2019-02-19 10:33:31 | CLASS ACTION UPDATE for DBVT, AGN, SVXY and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-19 10:23:44 | CLASS ACTION UPDATE for GS, XRAY, NVDA and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders